Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis

International Journal of Antimicrobial Agents

Volumn 48, Issue 5, 2016, Pages 542-546

  Tsai, Danny ^a,b   Stewart, Penelope ^b   Goud, Rajendra ^b   Gourley, Stephen ^b   Hewagama, Saliya ^b,c   Krishnaswamy, Sushena ^b,d   Wallis, Steven C ^a   Lipman, Jeffrey ^a,e   Roberts, Jason A ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ALICE SPRINGS HOSPITAL   (Australia)

^c NORTHERN HOSPITAL   (Australia)

^d SOUTHERN HEALTH   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Critically ill; Pharmacokinetics; Severe sepsis; Lactam

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ETHNICITY; FEMALE; HUMAN; INDIGENOUS AUSTRALIAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SEPSIS; AUSTRALIA; CHEMISTRY; CRITICAL ILLNESS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; POPULATION GROUP; PROSPECTIVE STUDY; TIME FACTOR; URINE; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AUSTRALIA; CRITICAL ILLNESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; POPULATION GROUPS; PROSPECTIVE STUDIES; SEPSIS; THIENAMYCINS; TIME FACTORS; URINE; YOUNG ADULT;

EID: 84994009060     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.08.015     Document Type: Article

References (19)

1. [1] Davis, J.S., Cheng, A.C., McMillan, M., Humphrey, A.B., Stephens, D.P., Anstey, N.M., Sepsis in the tropical Top End of Australia's Northern Territory: disease burden and impact on Indigenous Australians. Med J Aust 194 (2011), 519–524.
2. [2] Davis, J.S., He, V., Anstey, N.M., Condon, J.R., Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 year follow up. PLoS ONE, 9, 2014, e112224.
3. [3] Einsiedel, L.J., Woodman, R.J., Two nations: racial disparities in bloodstream infections recorded at Alice Springs Hospital, Central Australia, 2001–2005. Med J Aust 192 (2010), 567–571.
4. [4] Einsiedel, L., Fernandes, L., Woodman, R.J., Racial disparities in infection-related mortality at Alice Springs Hospital, Central Australia, 2000–2005. Med J Aust 188 (2008), 568–571.
5. [5] Tabah, A., De Waele, J., Lipman, J., Zahar, J.R., Cotta, M.O., Barton, G., et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70 (2015), 2671–2677.
6. [6] Craig, W.A., Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22 (1995), 89–96.
7. [7] Roberts, J.A., Lipman, J., Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37 (2009), 840–851 quiz 859.
8. [8] Tsai, D., Jamal, J.A., Davis, J.S., Lipman, J., Roberts, J.A., Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet 54 (2015), 243–260.
9. [9] Hoy, W.E., Hughson, M.D., Singh, G.R., Douglas-Denton, R., Bertram, J.F., Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int 70 (2006), 104–110.
10. [10] Kondalsamy-Chennakesavan, S., Hoy, W.E., Wang, Z., Briganti, E., Polkinghorne, K., Chadban, S., et al. Anthropometric measurements of Australian Aboriginal adults living in remote areas: comparison with nationally representative findings. Am J Hum Biol 20 (2008), 317–324.
11. [11] Griese, E.U., Ilett, K.F., Kitteringham, N.R., Eichelbaum, M., Powell, H., Spargo, R.M., et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from Western Australia. Pharmacogenetics 11 (2001), 69–76.
12. [12] Roberts, J.A., Kirkpatrick, C.M., Roberts, M.S., Robertson, T.A., Dalley, A.J., Lipman, J., Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64 (2009), 142–150.
13. [13] Neely, M.N., van Guilder, M.G., Yamada, W.M., Schumitzky, A., Jelliffe, R.W., Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34 (2012), 467–476.
14. [14] Kitzes-Cohen, R., Farin, D., Piva, G., De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 19 (2002), 105–110.
15. [15] Jaruratanasirikul, S., Thengyai, S., Wongpoowarak, W., Wattanavijitkul, T., Tangkitwanitjaroen, K., Sukarnjanaset, W., et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother 59 (2015), 2995–3001.
16. [16] Novelli, A., Adembri, C., Livi, P., Fallani, S., Mazzei, T., De Gaudio, A.R., Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44 (2005), 539–549.
17. [17] Australian Bureau of Statistics, Australian Aboriginal and Torres Strait Islander health survey: biomedical results, 2012–13. 2014, Australian Bureau of Statistics, Belconnen, ACT, Australia Contract No.: 4727.0.55.006.
18. [18] Roberts, J.A., Abdul-Aziz, M.H., Lipman, J., Mouton, J.W., Vinks, A.A., Felton, T.W., et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14 (2014), 498–509.
19. [19] Langan, K.M., Jacob, J., Li, J., Nation, R.L., Bellomo, R., Howden, B., et al. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study. Crit Care Resusc 16 (2014), 190–196.